It is claimed that inappropriate requesting of thyroid function tests (TFTs) is common in acutely ill patients. Consecutive inpatient TFTs (n=129) were assessed in relation to clinical history and common symptoms and signs of thyroid disease. Requests were justi®ed in 69% of cases, most commonly on the basis of atrial ®brillation and/or tachycardia. There were no clear reasons for requesting TFTs in the remaining cases, although the yield of abnormal results in these patients was similar to that in those with justi®ed requests. Thyroid stimulating hormone (TSH) concentration was increased (median 7´5 mU/L, range 4´8±38´6 mU/L) in 22 patients, six of whom had biochemical and/or clinical evidence of hypothyroidism (previously undiagnosed) and ®ve of whom had pre-existing hypothyroidism. Of the remaining 11 patients with increased TSH levels, three were con®rmed to have compensated hypothyroidism; non-thyroidal illness (NTI) (including the effect of drugs) accounted for four cases. In four patients (one of whom died during the admission) follow-up was not possible. Of six patients with reduced TSH concentration (range 0´05±0´35 mU/L), one was thyrotoxic on carbimazole, one was receiving thyroxine for hypothyroidism, one had NTI and three were lost to follow-up (two of whom died during their admission). Manifestations of thyroid disease are protean and often subtle, and TFTs are thus clinically justi®ed in many unwell inpatients. Although NTI contributes to some cases of abnormal TSH levels, a signi®cant number of TFT abnormalities are consistent with underlying thyroid abnormality requiring investigation/treatment.
Biochemical assessment of thyroid function in patients with non-thyroidal illness (NTI) is dif®cult, given that illness may cause both increased and decreased concentrations of thyroid stimulating hormone (TSH, thyrotrophin) and decreased concentrations of thyroid hormone. 1 Additionally, many drugs are known to interfere with thyroid function tests (TFTs), through both in vivo and in vitro actions. 2 In one oft-quoted study of a hospitalized population, 3 patients with low TSH concentrations were more likely to have NTI or to be receiving glucocorticoids than to have thyroid disease and, among those with a TSH concentration in the range 6´8±20 mU/L, NTI was six times as common as intrinsic thyroid disease.
In view of this, the consensus view in the literature 2,4±6 has been that TFTs should not be requested in ill patients unless there are clinical grounds for suspecting that thyroid dysfunction may be contributing to their clinical condition. Additionally, it is a widely held belief that unnecessary requesting of TFTs is common among patients admitted to hospital. 1, 4, 5 We have assessed the appropriateness of thyroid function testing in an inpatient population, in the context of common symptoms and signs of underlying thyroid disease and/or a clinical history rendering thyroid disease more likely.
METHODS
During a 1-month period, 156 consecutive inpatient TFTs on 143 adult patients (13 patients had multiple requests) were identi®ed using the laboratory computer system and the patients' clinical notes were recalled. In 12 cases the notes were not available, and two patients were excluded because the notes were incomplete. Consequently, 129 patient episodes (42 men, 87 women) were studied. The mean age was 69 years (median 74 years, range 23±95 years).
This study was conducted in a 420-bed district general hospital serving a resident population of approximately 175 000. The hospital has an accident and emergency unit and a medical admissions ward and, additionally, supports a subregional renal unit. TFTs were generally requested at, or soon after, the time of admission. The majority of patients were admitted to general medical wards; no patients were on the intensive treatment unit. Presenting symptoms are shown in Table 1 .
In all patients TSH was measured as a frontline test, with free thyroxine (fT 4 ) being reserved for cases in which the TSH concentration was abnormal. Hormones were measured using an Abbott AxSYM analytical system (Abbott Laboratories Ltd, Maidenhead, UK). The reference ranges for TSH and fT 4 were 0´49± 4´7 mU/L and 9´1±23´8 pmol/L, respectively.
A request for TFTs was considered to be justi®ed if the clinical history increased the probability of thyroid disease contributing to the presenting complaint and/or if there were common symptoms or signs of thyroid disease (see Table 2 ). 4,6±8 A full drug history was recorded to establish whether drug interferences were a common problem in the interpretation of TFTs; in particular, drug treatment with amiodarone or lithium was considered to be a reasonable indication for requesting a TFT in an unwell patient. 8 For patients who were found to have abnormal TFTs, the clinical notes and laboratory computer system were reviewed again 1 year later to establish whether the thyroid abnormality had persisted following discharge. If no further TFTs were available the patient's general practitioner was contacted directly with a request for further information and repeat investigations. For those cases in which either the patient died shortly after admission or direct contact with the general practitioner failed to elicit a further TFT request, the patient was classi®ed as`lost to follow-up'.
RESULTS
TFTs were felt to be clinically justi®ed in 89 (69%) cases (see Fig. 1 ). Of these 89 cases, the TSH concentration was above the reference range in 17 (median 7´9 mU/L, range 4´8± 25´5 mU/L) and below the reference range in six (range 0´05±0´35 mU/L). There were no clear reasons for requesting TFTs in 40 (31%) cases; TSH concentrations were increased in ®ve of these patients (median 7´0 mU/L, range 5´0± 38´6 mU/L) but none had TSH concentrations below the reference range.
The yield of abnormal results in the`clinically unjusti®ed' group did not differ signi®cantly from that in patients with clinical indications for thyroid investigation ( 2 with Yates' correction 2´16, P=0´14).
The clinical and biochemical features of patients with abnormal TFTs are summarized in Table 3 . Of the 22 patients with increased TSH concentration, six had biochemical and/or clinical evidence of hypothyroidism, none of whom were previously known to be hypothyroid. Five patients were known to have preexisting hypothyroidism, and in three of these the dose of thyroxine was increased on the basis of the TFT results.
Of the remaining 11 patients with raised TSH and no record of pre-existing thyroid disease, three had compensated hypothyroidism with a have been low due to pregnancy, 5 but no postpartum follow-up results were available. One patient presumably had abnormal TFTs as a result of NTI since he had a normal serum TSH concentration after discharge. Two patients died during their admission before follow-up TFTs were taken.
DISCUSSION
Against a standard of the common clinical features of thyroid disease, the majority of inpatient TFT requests appeared justi®able, although the abnormal results detected in this way rarely re¯ected the clinical indication (e.g. no patients with weight loss or atrial ®brillation were found to have thyrotoxicosis but a signi®cant number of them did have increased TSH concentrations). Although NTI may have accounted for some of the abnormal TFTs observed in the seven patients who were lost to follow-up (three of whom died during their admission), it could only be con®rmed as the explanation for one case of low serum TSH concentration and three cases of increased serum TSH concentration observed in this study. NTI did not appear to cause inappropriate management or interpretative dif®culty in these cases, with TSH estimation being appropriately repeated when these patients were followed-up after discharge from hospital. In only one case did drug interference (amiodarone) appear to contribute to an abnormal TFT result.
Our study supports the suggestion that TFTs may be abnormal in the hospital setting as a result of NTI, but the magnitude of this problem would appear to be lower than that observed in the earlier study of Spencer et al. 3 In contrast to that study, of the 12 patients with TSH concentrations in excess of 6´8 mU/L, 11 were found to have intrinsic thyroid disease. Although six patients had TSH concentrations below the reference range, in only one was it suppressed below the detection limit of the assay; this patient was a known thyrotoxic. The number of patients in this present study is considerably smaller than in the study of Spencer et al. 3 However, in their study, TFTs were not actually requested; instead, all samples passing through a hospital laboratory (and for which there was suf®cient sample volume) were processed for TFTs. The population in that study included a high percentage of patients receiving glucocorticoids and/or with chronic renal failure. Additionally, the mean age of the patients was 44 years, considerably younger than in the present study and than the average age of acutely ill patients presenting to a general hospital. Consequently, their conclusions may not be transferable to routine clinical practice.
Clearly, NTIs and drugs can affect TFT results. However, this needs to be balanced against the new cases of hypothyroidism detected in this population and the cases of hypothyroidism in which replacement treatment may have been inadequate (either as a result of non-compliance or too small a dose). In our experience, a signi®cant number of TFT abnormalities observed in the setting of acutely ill hospitalized patients are consistent with underlying thyroid abnormality requiring investigation or treatment, particularly at higher concentrations of TSH ( 6´8 mU/L).
We identi®ed that abnormal thyroid function results were commonly not followed with appropriate further investigation and treatment, and this is a cause for concern. For example, evidence of inadequate replacement in patients with known hypothyroidism was not always acted upon. In some cases, clearly abnormal TFTs were not documented in discharge summaries, leading to a signi®cant delay in instituting appropriate further investigations and treatment. Patients with apparently compensated hypothyroidism commonly did not have thyroid antibodies measured, 8 even though, in the hospital setting, the presence of thyroid antibodies appears to be a useful discriminator between intrinsic thyroid disease and NTI. 3
CONCLUSION
Like all laboratory tests, TFTs should only be requested when clinically indicated. However, the manifestations of thyroid disease are so protean, and in many cases subtle, that requests may be justi®ed in many unwell patients admitted to hospital. Indeed, in many of the patients in this study, it would have been remiss not to have requested a TFT. It is important that clinicians remain aware of the effects of NTI on TFTs and of the poor speci®city of TSH in this situation. However, in clinical practice, thyroid dysfunction will often appear in the differential diagnosis of the acutely ill patient, particularly in the elderly. We would agree with Beckett and Wilkinson 1 that, faced with such potentially clinically important results, clinical biochemists must assist clinicians in the interpretation and further investigation of these patients.
